Skip to content
Review

Abstract 13854: Comparative Efficacy and Safety of Aldosterone Synthase Inhibitors versus Mineralocorticoid Receptor Antagonists for Resistant Hypertension: A Systematic Review and Network Meta-Analysis

Nov 2026 · Circulation · 0 citations

Abstract

Introduction: Resistant hypertension often persists despite multidrug therapy, driven by unopposed aldosterone activity. In May 2026, the FDA approved baxdrostat, a first-in-class aldosterone synthase inhibitor. Other agents include mineralocorticoid receptor antagonists (MRAs) such as spironolactone and eplerenone. This network meta-analysis compares their efficacy and safety. Methods: We searched major databases for rcts comparing ASIs (baxdrostat, lorundrostat) or MRAs (spironolactone, eplerenone, finerenone) to placebo or each other in resistant hypertension. Primary outcome: change in systolic blood pressure. A Bayesian network meta-analysis was performed using the R meta package. Risk of bias was assessed using ROBS 2.0. Results: A total of 12 RCTs (N=4,267) were included; 58% male, 42% female. Treatment arms: baxdrostat 2 mg (n=393), baxdrostat 1 mg (n=395), placebo (n=397), spironolactone (n=230), eplerenone (n=78), finerenone (n=624), lorundrostat 50 mg (n=542), esaxerenone (n=260). For SBP reduction, baxdrostat 2 mg showed -9.8 mmHg (95% CI -12.6 to -7.0) with highest SUCRA (77%), followed by spironolactone (69%; -20.1 mmHg, 95% CI -31.2 to -9.1) and eplerenone (58%; -8.1 mmHg, 95% CI -8.2 to -8.0). For DBP reduction, spironolactone ranked highest (SUCRA 71%; -5.7 mmHg, 95% CI -8.1 to -3.3), baxdrostat 2 mg achieved -3.9 mmHg (95% CI -5.7 to -2.0). For hyperkalemia (lower SUCRA better), finerenone ranked best (0.95), baxdrostat second (0.81). Hyperkalemia (>6.0 mEq/L) incidence: baxdrostat 2 mg 3.0%, spironolactone 9.6% (95% CI 1.6-40.6). No drug-related deaths occurred. Conclusion: Baxdrostat, a first-in-class aldosterone synthase inhibitor, demonstrates comparable blood pressure reduction to spironolactone in resistant hypertension but with a significantly lower risk of hyperkalemia. It represents a promising new add-on therapy, particularly for patients intolerant to or at high risk from mineralocorticoid receptor antagonists. Further long-term cardiovascular outcome trials are warranted. Risk of bias was low.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.